Andrew, I don’t know if the inherited retinal disease ASO program they have selected is aimed at a specific interested party, but I strongly suspect so.
I believe that there is ongoing engagement with multiple pharmas who have expressed interest in using the CPP platform with different proprietary molecules. My understanding is that, in order to achieve the type of payments PYC is seeking in future deals, the tech needs to be progressed into the clinic for therapeutic validation. Hence, this is the current priority.
PYC Price at posting:
3.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)